Evidence map›Paper›PMID 36033758›Full record

ReviewFrontiers in public health2022

Determining SARS-CoV-2 non-infectivity state-A brief overview.

Siggeir F Brynjolfsson, Hildur Sigurgrimsdottir, Olafur Gudlaugsson, Mar Kristjansson, Karl G Kristinsson, Bjorn R Ludviksson

Abstract readReview
In one paragraph

Review in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Siggeir F BrynjolfssonDepartment of Immunology, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
Hildur SigurgrimsdottirDepartment of Immunology, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
Olafur GudlaugssonDepartment of Infectious Diseases, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
Mar KristjanssonDepartment of Medicine, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Karl G KristinssonDepartment of Medicine, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Bjorn R LudvikssonDepartment of Immunology, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

From the beginning of the COVID-19 pandemic, it has claimed over 6 million lives, and globally the pandemic rages with detrimental consequences, with the emergence of new more infectious and possibly virulent variants. A clinical obstacle in this battle has been to determine when an infected individual has reached a non-infectious state. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can be transmitted under diverse circumstances, and various rules and regulations, along with different testing methods, have been applied in an attempt to confine the transmission. However, that has proven to be a difficult task. In this review, we take together recently published data on infectivity and transmission of SARS-CoV-2 and have combined it with the clinical experience that physicians in Iceland have accumulated from the pandemic. In addition, we suggest guidelines for determining when patients with COVID-19 reach a non-infectious state based on a combination of clinical experience, scientific data, and proficient use of available tests. This review has addressed some of the questions regarding contagiousness and immunity against SARS-CoV-2.

Indexed as

COVID-19HumansPandemicsSARS-CoV-2COVID-19non-infectious stateSARS-CoV-2transmission of SARS-CoV-2viral testing

Identifiers

PMID36033758
PMCPMC9412020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.